Tobramycin for Pseudomonas infection in bronchiectasis
Part of Infections, Lungs & breathing clinical trials.
This study looks at the long-term effects of using an inhaled antibiotic called tobramycin to get rid of Pseudomonas aeruginosa bacteria in people with bronchiectasis. It may help keep the infection away and improve breathing health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have already taken part in the ERASE study.
- You must be willing to sign a consent form agreeing to join this follow-up study.
- You were not lost to follow-up in the earlier ERASE study.
- The study doctor agrees you are eligible to continue.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a common antibiotic called azithromycin can help prevent flare-ups (sudden worsening) of bronchiectasis—a lung condition where airways become permanently enlarged and damaged. Patients will take azithromycin or a placebo for 12 months to see if it reduces how often they get sick.
This trial tests two different antibiotic treatments for adults with bronchiectasis who have a new or recent infection with Pseudomonas aeruginosa (PA) bacteria in their airways. The goal is to see which regimen works better to clear the infection early.
This study looks at how bacteria live in the lungs of people with bronchiectasis and how they may adapt over time. It may help researchers understand why infections keep coming back and how to better manage chronic lung colonization.
This study looks at why bronchiectasis gets worse over time. It may help doctors understand the disease better and find better ways to monitor or treat it.
This study tests a new medicine (AZD0292) given through a vein for people with bronchiectasis and a chronic Pseudomonas lung infection. It aims to see if it can reduce flare-ups and improve lung health.
This study tests a new medication called AZD0292 for people with bronchiectasis who have a long-term Pseudomonas infection. It aims to see if the drug can reduce flare-ups and improve lung health.
Hear when a new Bronchiectasis Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.